Cartesian Therapeutics, Inc.
RNAC· Nasdaq
RNACCartesian Therapeutics, Inc.
Filed Aug 9, 2016 · 10-Q · 40 days after period end · 0001558370-16-007812
| Metric | Q2 2016 | Q2 2015 |
|---|---|---|
| Revenue | $2.02M | $1.24M |
| Net Income | -$6.92M | -$6.87M |
| EPS Diluted | -$2.75 | -$3.93 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cartesian Therapeutics, Inc. · CIK 1453687 · Engraved from SEC EDGAR
ended Jun 30, 2016 · filed Aug 9, 2016 · 40 d after period end
